Xenon Pharmaceuticals' (XENE) partner Genentech, a member of the Roche (RHHBY) Group, has advanced a second Nav1.7 inhibitor into clinical development. GDC-0310 is a selective, oral Nav1.7 small-molecule inhibitor, identified as part of the companies' pain collaboration focused on the Nav1.7 target. Genentech has initiated a Phase 1 clinical trial in healthy volunteers for GDC-0310. Genentech is also developing GDC-0276, a selective, oral Nav1.7 small-molecule inhibitor for pain which is currently in a Phase 1 clinical trial. Nav1.7 appears to be involved in pain signaling and based on the human validation was selected as a key target for the development of novel analgesics.